<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="89133">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02031952</url>
  </required_header>
  <id_info>
    <org_study_id>Rvrl2005</org_study_id>
    <nct_id>NCT02031952</nct_id>
  </id_info>
  <brief_title>Hepatectomy Versus Hepatectomy With Lymphadenectomy in Hepatocellular Carcinoma</brief_title>
  <official_title>Hepatectomy Versus Hepatectomy With Lymphadenectomy in Hepatocellular Carcinoma ----A Prospective Randomized Controlled Clinical Trail</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <authority>China: Ethics Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The preventive lymphadenectomy is not performed routinely for hepatocellular carcinoma (HCC)
      patients in clinical practice. While many patients suffered the recurrence without the
      evidence of portal or hepatic vascular invasion or multiple loci, it lead to reconsider the
      value of preventive resection of regional lymph node for those patients. Recently, more and
      more studies had found the incidence of lymph node metastasis was higher in autopsy specimen
      than those in operable patients.

      This project is a prospective randomized controlled trial, planning to compare hepatectomy
      with hepatectomy combined lymphadenectomy regarding of the safety and efficacy in HCC
      patients, to reach a further understanding of the role of lymphadenectomy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2005</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Recurrence-free survival</measure>
    <time_frame>5 year</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The recurrence-free survival time was defined as the time from the date of resection or ablation to the time of recurrence, metastasis or last follow-up.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Post-operation complication</measure>
    <time_frame>90-d after surgery</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">87</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>hepatectomy combined lymphadenectomy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>hepatectomy combined lymphadenectomy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>hepatectomy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>hepatectomy alone</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>hepatectomy combined with lymphadenectomy</intervention_name>
    <arm_group_label>hepatectomy combined lymphadenectomy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>hepatectomy alone</intervention_name>
    <arm_group_label>hepatectomy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age 18 to 65 years;

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status is grade 0 or 1;

          -  good liver function with Pugh-Child Class A or B;

          -  indocyanine green retention at 15 minutes (ICG-R15) &lt;15%;

          -  without severe cirrhosis;

          -  the diameter of tumor is equal to or more than 3 cm;

          -  the liver resection could be assessed R0 (the define of R0 resection will be
             explained in the section of Surgical procedures);

          -  absence of extrahepatic metastasis.

        Exclusion Criteria:

          -  the diameter of tumor is less than 3 cm;

          -  palliative resection of tumor;

          -  with the history of hepatic encephalopathy, ascites, and variceal bleeding;

          -  with severe hepatic cirrhosis;

          -  tumor rupture;

          -  with the history of upper abdominal surgery, it is tough to remove the regional lymph
             nodes; or it is unable to be resected when multiple lymph nodes mixed and fixed.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yunfei Yuan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center</name>
      <address>
        <city>GuangZhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 8, 2014</lastchanged_date>
  <firstreceived_date>January 4, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Yunfei Yuan</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>hepatocellular carcinoma</keyword>
  <keyword>hepatectomy</keyword>
  <keyword>lymphadenectomy</keyword>
  <keyword>complication</keyword>
  <keyword>prognosis</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
